吡格列酮对血液透析患者心血管疾病危险因素的影响

吡格列酮对血液透析患者心血管疾病危险因素的影响

肖长长

东莞市厚街医院

收稿日期:2014-11-27 修回日期:2014-11-27 出版日期:2015-02-25 发布日期:2015-01-25

The impact of pioglitazone on cardiovascular disease risk factors in hemodialysis patients xiao zhuangzhang,jiang huifang,Luo jiuyuan,Hu zhihui,Lou zhongming,Liu lanxia,Li guilan,Zhang yue. Houjie Hospital ,523945,china

Dongguan houjie hospital

Received:2014-11-27 Revised:2014-11-27 Online:2015-02-25 Published:2015-01-25

摘要/Abstract

摘要： 【】目的观察过氧化物酶增殖体激活受体γ(PPARγ)激活剂吡格列酮对维持性血液透析患者心血管疾病危险因素的影响。方法33例维持性血液透析患者应用吡格列酮(30mg/d)治疗8周,分别于用药前、用药8周后观察患者收缩压(SBP)、舒张压(DBP)、血浆低密度脂蛋白(LDLD)、总胆固醇(CHOL)、高敏C反应蛋白(hs-CRP)、超氧化物歧化酶(SOD)、白细胞介素6(IL-6)、同型半胱氨酸(Hcy)、水平。结果吡格列酮治疗维持性血液透析患者8周后,SBP、DBP、LDLD、CHOL、hs-CRP、IL-6、Hcy水平下降,差异有统计学意义(P＜0.05),SOD水平较治疗前明显上升,差异有统计学意义(P＜0.01)。结论吡格列酮能改善维持性血液透析患者的心血管疾病危险因素。

Abstract: 【】 Objective Observing peroxisome proliferator-ativated receptor-γ(PPARγ)agonit-pioglitazone impacted the cardiovascular risk factors in hemodialysis patients. Methods Thirty three patients on regular hemodialysis were treated with pioglitazone(30mg/d) for 8 weeks. The systolic blood pressure(SBP),diastolic blood pressure(DBP),plasma level of low density lipoprotein(LDLD),cholesterol total(CHOL),high sensitive C-reactive protein(hs-CRP),superoxide dismutase(SOD),interleukin 6(IL-6),homocysteine(Hcy)were observed before and after 8 weeks(8W). Results SBP、DBP、LDLD、CHOL、hs-CRP、IL-6、Hcy decreased after 8W of therapy(P＜0.05),SOD increased significantly after 8W(P＜0.01). Conclusions Pioglitazone can reduce the cardiovascular risk factors in maintenance hemodialysis patients.

肖长长. 吡格列酮对血液透析患者心血管疾病危险因素的影响[J]. .

参考文献

[1]王海燕.慢性肾脏病的心血管病变.肾脏病学(第3版),2008,27:1883-1896.
[2] Nusair M.B,Rajpurohit N,Alpert M.A．Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease. Clin J Am Soc Nephrol 4: S49–S55, 2009.
[3] Inkster B,Zammitt NN,Frier BM．Drug-induced hypoglycaemia in type 2 diabetes[J]．Expert Opin Drug Saf,2012,11:597—614.
[4]姜惠芳,彭兰芬,肖长长等.过氧化物酶增殖体激活受体γ(PPARγ)激活剂吡格列酮对血液透析患者的非降糖作用[J].国际移植与血液净化杂志,2014,5(12):45-47.
[5]Sugawara A,Uruno A,Kudo M.Effects of PPARγon hypertension,atherosclerosis,and chronic kidney disease.Endocrine Journal. 2010,57(12):433-435.
[6]周宇,张庆梅,薛萌.吡格列酮对原发性高血压合并2型糖尿病血管内皮功能的影响.黑龙江医学. 2011,3(35):15-19.
[7]Akira S,Akira U,Ken M.Effects of PPARγagonists against vascular and renal dysfunction.Curr Molec Pharmocol.2012,5(14):189 -191.
[8] 朱辟疆.慢性肾衰竭与微炎症状态[会议论文]. 2007年第9届全国中西医结合肾脏病学术会议.
[9] Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis. Nephrology.2012,17(6): 545-551.
[10] Shakeri A,Tabibi H,Hedayati M.Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int.2010,14(4):498-504.
[11]Chunjie H,Juntian L,Ming L.Rosightazone inhibits angiotensin Ⅱ-induced C-reactive protein production in human aortic endothelial cells through regulating AT1-ROS-MAPK signal pathway.Inflammation Research , 2012,6(61):223-226.
[12]Tomotaka D,Katsumi M,Takafumi I.Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.Circu J.2011,75(6):467 -469.